---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000019"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:47:25.803407+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Virios Therapeutics: FDA alignment on Phase 3 fibromyalgia and Phase 2 Long-COVID endpoint clarity

## Summary
- FDA agreed on Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia treatment.
- FDA accepted fatigue as primary endpoint and orthostatic intolerance as key secondary for IMC-2 Long-COVID Phase 2 study.
- Company provided unrestricted grant to Bateman Horne Center for placebo-controlled study of up to 60 LC patients on IMC-2.
- New international patent application filed for IMC-2 as treatment for Long-COVID and fatigue conditions.
- Company has capital to support operations into Q4 2024; exploring M&A opportunities.

## SEC filing metadata
- accession: 0001558370-24-000019
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024000019/0001558370-24-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024000019/tmb-20240103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000019
- JSON: https://secwatch.observer/filing/0001558370-24-000019.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.